Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Asahi Kasei Pharma: Famvir Shore Up Sales, Profits
November 24, 2008
- Suzuken: Sales Up 3.8%, Operating Profits Down 29.7%
November 24, 2008
- Teijin: Bonalon, Home Care Business Drive Business
November 24, 2008
- Toho: Net Losses due to Bankruptcy of Fuji Biomedix
November 24, 2008
- Meiji Seika: Sales of Generics Up 38.9%
November 24, 2008
- Nihon Chouzai: Investment in Generics Business Depresses Profitability
November 24, 2008
- Ajinomoto: Pharma Sales Up 1.0% to \42.9 Bil.
November 24, 2008
- QOL: Acquisition Boosts Sales by 52%
November 24, 2008
- BUSINESS NEWS IN BRIEF
November 24, 2008
- Wholesale Business Management Seminar
November 24, 2008
- ASKA, Actavis Create Generic Joint Venture Firm in Japan
November 24, 2008
- Santen to Recover Market Share with Tafluprost
November 24, 2008
- DPC Has Increased Use of Generics in over 60 DPC Hospitals: JHA Survey
November 24, 2008
- Kaken: Artz's Sales Up 9.1% Despite NHI Price Cut of 5.8%
November 24, 2008
- Daiichi Sankyo Ties Up with ArQule for Oncology Therapeutics
November 24, 2008
- Kyorin: First Net Loss due to Withdrawal of Gatifloxacin
November 24, 2008
- R&D NEWS IN BRIEF
November 24, 2008
- Mochida: Forecasts for Both Sales and Profits Revised Upward
November 24, 2008
- Chuikyo Will Continue to Review FPMAJ's Drug Pricing System Reform Proposal: Mr Nagano
November 24, 2008
- Kissei: New Products Make Up for Drop in Sales of Cabaser
November 24, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…